We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Galimedix is a Phase 2 US/Israel clinical stage ophthalmic biopharma company developing truly novel and transformative treatments based on a novel mechanism of action directed to the common cause of many neurodegenerative diseases: toxic oligomers of amyloid beta. Lead product, GAL-101, is an eye drop for treatment to slow progression of dry macular degeneration of the retina, and glaucoma: two of the leading causes of blindness. Led by a highly experienced biopharma team including many ex-Pharma executives, Galimedix has an exclusive worldwide license from Tel Aviv University and German-based Merz Pharmaceuticals, where the compound was developed for seven years through Phase I. A next generation, potentially superior compound, GAL-201, is in preclinical development for oral administration, with the potential to treat CNS diseases such as Alzheimer’s. The Board of Directors and scientific advisors include many leading names in the field of glaucoma and retinal disease.